Latest News about Lymphoma
Recent news which mentions Lymphoma
   Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration
   
  
  
  May 01, 2023
  From Benzinga
 
   Discover Cord Blood’s Life-Saving Benefits at the 7th Annual Arizona Cord Blood Conference – United by Our Strengths
   
  
  March 07, 2022
  From PRUnderground
 
   Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
   
  December 14, 2021
  Tickers 
   GILD
  
  
  From Benzinga
 
   Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation
   
  December 13, 2021
  Tickers 
   VIRX
  
  
  From Benzinga
 
   Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting
   
  December 13, 2021
  Tickers 
   JAZZ
  
  
  From Benzinga
 
   Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
   
  
  
  December 13, 2021
  From Benzinga
 
   TG Therapeutics Shares Plunge After FDA Plans AdComm Meet For Blood Cancer Candidate
   
  November 30, 2021
  Tickers 
   TGTX
  
  
  From Benzinga
 From PRLog
 
   Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting
   
  October 01, 2021
  Tickers 
   GILD
  
  
  From Benzinga
 
   BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma
   
  September 15, 2021
  Tickers 
   BGNE
  
  
  From Benzinga
 
   Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response
   
  August 20, 2021
  Tickers 
   FATE
  
  
  From Benzinga
 
   BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma
   
  July 26, 2021
  Tickers 
   BGNE
  
  
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.